Coccidioidomycosis (Valley Fever or Cocci): Making a Difference in Primary and Emergency Medicine/Urgent Care

Why Care About Valley Fever?

  • Coccidioidomycosis, also known as Valley Fever or Cocci, can present as community-acquired pneumonia (CAP) that is difficult to distinguish from viral or bacterial CAP. In fact, Cocci is a common cause of CAP in highly endemic regions, resulting in approximately 15% to 30% of cases in Tucson and Phoenix.
  • Approximately 20 000 cases of Cocci are reported each year in the United States.
  • Cocci is frequently misdiagnosed, underdiagnosed, or missed because patients don’t seek care. Centers for Disease Control and Prevention (CDC) recently estimated that the true annual burden of Valley Fever may be 10-18 times higher than previously reported (upwards of 206 000 to 360 000 cases).
  • Patients with misdiagnosed Cocci may receive multiple rounds of antibiotics unnecessarily. In some cases, the disease can disseminate beyond the lungs, causing long-term disability or death. CDC recently estimated that 700-1100 deaths are due to Cocci per year.
  • A recent study conducted in a Medicare population found that the Cocci rate exceeded 100 cases/100 000 person-years in 339 US counties. Given the acceptability of testing for Legionnaire’s disease (approximately 2 cases/100 000 person-years) and pulmonary embolism (approximately 112 cases/100 000 person-years), testing for Cocci is well justified in affected regions.
  • Early diagnosis and effective management of Cocci can help prevent progression to severe or disseminated forms, reducing morbidity and mortality.

What Is It?

  • Coccidioidomycosis is an infection caused by inhaling spores of Coccidioides species—soil-dwelling fungi found in the southwestern United States, Washington State, and parts of Central and South America.
  • Common symptoms of Valley Fever include cough, shortness of breath, fatigue, fever, and red to purple nodules on the skin known as erythema nodosum.
  • Most people infected with Coccidioides experience mild or self-limited symptoms, but 5-10% develop a chronic pulmonary infection or disseminated disease. Recently, investigators have found an association between Cocci and the development of asthma.
  • Certain populations are at risk for severe or disseminated Cocci. This includes people of African or Oceanic genomic ancestry, those with immunodeficiency, and pregnant women.

Where Does It Occur?

  • Coccidioidomycosis lives in dry regions, including the southwestern United States, and parts of Washington State. Travel to these areas—even brief visits—may be enough to cause infection.
  • Cocci also occurs in Central and South America. Maps of the regions affected by Cocci are shown.

Approximate range of Coccidioides in the United States. Courtesy of CDC.

Approximate range of Coccidioides in the world. Courtesy of CDC.

 

Outbreak potential: Although most cases are sporadic, outbreaks can occur after soil disruption from construction, excavation, wildfires, other natural disasters, or dust storms. Occupational and environmental exposures should raise suspicion in symptomatic patients.

When Should I Test?

Consider testing for Cocci in a patient who has lived in or traveled to the endemic region and has

  • CAP or erythema nodosum following recent respiratory symptoms who:
    • Has a link to a known outbreak,  OR
    • Lives in or has recently traveled to highly endemic regions, including
      • Desert regions of South-Central Arizona.
      • San Joaquin Valley of California.
  • CAP that has not improved following a round of empiric antibiotics.

Clinical Pearl:

Erythema nodosum in conjunction with respiratory symptoms in a person who has been to the endemic region is a good diagnostic clue. In addition, the finding of eosinophilia on the routine differential in a person with CAP can also push you toward a Cocci diagnosis.

How Can I Diagnose It?

Refer to the CDC’s Coccidioidomycosis Testing Algorithm. Common initial tests include the following serologic tests:

  • Enzyme immunoassays (EIA) for IgM and IgG
  • Immunodiffusion tests (ID)
  • Complement fixation (CF)
  • If EIA is used, follow-up with ID/CF is recommended due to false positives.

Testing interpretation can vary depending on the patient’s immune status and timing of illness onset.

CHECK OUT…

PCP/Emergency Medicine Physicians Making a Difference in Cocci

Hear from Dr Mike Tushla, a family physician from Santa Paula, California, about his experience in caring for patients with Cocci.

Click Here to Download a PDF Transcript of the Video

 

Patient Experience With Cocci

Listen to Larry’s and Kippi’s journey with Cocci and the challenges associated with living with the disease.

Faces of Fungal Infection Videos – Fungus Education Hub

Need Help? Get a Clinical Consult!

Healthcare providers can call 404-639-5168 or email fungalconsult@cdc.gov for consultation on diagnosis or treatment for suspected or confirmed fungal diseases.

RESOURCES

  • Benedict K, Smith DJ, Haczku A, et al. Investigating asthma after coccidioidomycosis among patients with commercial health insurance, United States, 2017-2022. Mycoses. 2025; 68(2):e70033. doi:10.1111/myc.70033
  • Centers for Disease Control and Prevention. Valley Fever (Coccidioidomycosis): clinical overview of Valley Fever. 2025. Accessed July 28, 2025. https://www.cdc.gov/valley-fever/hcp/clinical-overview/index.html
  • Centers for Disease Control and Prevention. Valley Fever (Coccidioidomycosis): reported cases of Valley Fever. 2025. Accessed July 20, 2025. https://www.cdc.gov/valley-fever/php/statistics/index.html
  • Mazi PB, Sahrmann JM, Olsen MA, et al. The geographic distribution of dimorphic mycoses in the United States for the modern era. Clin Infect Dis. 2023;76(7):1295–1301. doi:10.1093/cid/ciac882
  • Smith DJ, Free RJ, Thompson GR 3rd, et al. Clinical testing guidance for coccidioidomycosis, histoplasmosis, and blastomycosis in patients with community-acquired pneumonia for primary and urgent care providers. Clin Infect Dis. 2024;78(6):1559-1563. doi:10.1093/cid/ciad619
  • Williams SL, Benedict K, Jackson BR, et al. Estimated burden of coccidioidomycosis. JAMA Netw Open. 2025;8(6):e2513572. doi:10.1001/jamanetworkopen.2025.13572

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of the CDC or HHS and should not be considered an endorsement by the Federal Government.